Condition: COVID-19 · SARS-CoV-2 Viraemia · Monkey Pox · Sponsor: Centre Hospitalier Régional d'Orléans
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
This description comes directly from the study's public registry record.
Thierry PRAZUCK, Dr · 0238229593 · thierry.prazuck@chu-orleans.fr
Always discuss trial participation with your own doctor first.
| CHU Orléans | Orléans, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07085611